Antiretroviral Resistance

Module 10, Version 4

References

  • Abela IA, Scherrer AU, Böni J, et al. Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy Is observed in socially disadvantaged patients. Clin Infect Dis. 2020;70(2):297-303.
  • Alvarez M, Casas P, de Salazar A, et al. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: Implications for clinical practice. J Antimicrob Chemother. 2019;74(6):1693-1700.
  • Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci USA. 2009;106:5318-5323.
  • Andreatta K, Willkom, M, Martin R, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. J Antimicrob Chemother. 2019; 74(12):3555–3564.
  • Baxter JD, Dunn D, White E, et al. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment Trial. HIV Med. 2015 Apr;16(1):77-87.
  • Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83-F93.
  • Carganico A, Dupke S, Ehret R, Berg T, Baumgarten A, Obermeier M, and Walter H. New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy. J Int AIDS Soc. 2014;17(4 Suppl 3):19749.
  • Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 Study. J Infect Dis. 2014;210:354-362.
  • Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-588.
  • Cohen CJ, Molina JM, Cahn P. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV-1-infected patients: Pooled results from the phase III double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60:33-42.
  • Das K, Arnold E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr Opin Virol. 2013;3:119-128.
  • Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet. 1999;353:2195-2199.
  • Gagliardini R, Ciccullo A, Borghetti A, et al. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. Open Forum Infect Dis. 2018;5(6):ofy113.
  • Goetz M, Leduc R, Kostman J, et al. HIV replicative capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr. 2010;53:472-479.
  • Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, and Roger M. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother. 2015;70(2):405-411.
  • Hatano H, Lampiris H, Fransen S, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;54:389-393.
  • Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2020;382:1232-1243.
  • Lataillade M, Zhou N, Joshi SR, et al. Viral drug resistance through 48 weeks, in a phase 2b, randomized, controlled trial of the HIV-1 attachment inhibitor prodrug, fostemsavir. J Acquir Immune Defic Syndr. 2018;77:299-307.
  • Li Z, Zhou N, Sun Y, et al. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrob Agents Chemother. 2013;57:4172-4180.
  • Mazzuti L, Melengu T, Falasca F, et al. Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience. J Glob Antimicrob Resist. 2020;20:298-303.
  • McGee KS, Okeke NL, Hurt CB, et al. Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naïve Patient. Open Forum Infect Dis. 2018;5(11):ofy294. (https://doi.org/10.1093/ofid/ofy294).
  • McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: A retrospective analysis using screening, samples from the A4001029 and MOTIVATE studies. AIDS. 2010;24:2517-2525.
  • Miller V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr. 2001;26 Suppl 1:S34-S50.
  • Molina JM, Cahn P, Grinsztejn, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): A phase III randomised double-blind active-controlled trial. Lancet. 2011;378:238-246.
  • Nowicka-Sans B, Gong YF, McAuliffe B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012;56:3498-3507.
  • Ray N, Hwang C, Healy MD, et al. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr. 2013;64:7-15.
  • Raymond S, Delobel P, Mavigner M, et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS. 2008;22:F11-F16.
  • Saag MS, Gandhi RT, Hoy Jf et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324(16):1651-1669.
  • Santoro MM, Fornabaio C, Malena M, et al. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. Int J Antimicrob Agents. 2020;106027.
  • Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV. Clin Infect Dis. 2020;ciaa988. [Online ahead of print]
  • Scherrer AU, von Wyl V, Yan W, et al. Emergence of acquired HIV-1 drug resistance almost stopped in Switzerland: A 15-year prospective cohort analysis. Clin Infect Dis. 2016;62(10):1310-1317.
  • Shafer RW, Hertogs K, Zolopa AR, et al. High degree of interlaboratory reproducibility of Human Immunodeficiency Virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiology. 2001;39:1522-1529.
  • Sterrantino G, Borghi V, Callegaro AP, et al. Prevalence of predicted resistance to doravirine in HIV-1 positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019;53(4):515-519.
  • Talbot A, Grant P, Taylor J, et al. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: An independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother. 2010;54:2473-2479.
  • Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS. 2002;16:209-218.
  • Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS. 2010;24:503-514.
  • Visseaux B, Assoumou L, Mahjoub N, et al. Surveillance of HIV-1 primary infections in France from 2014 to 2016: Toward stable resistance, but higher diversity, clustering and virulence? J Antimicrob Chemother. 2020;75(1):183-193.
  • Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;27(3):111-121.
  • Wijting I, Rokx C, Boucher C, et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV. 2017;4(12):e547-e554.
  • Yang W, Kouyos R., Scherrer A, et al. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV cohort study from 1998 to 2012. J Infect Dis. 2015;212:28-38.
  • Young, Fransen S, Greenberg KS, et al. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther. 2011;16:253-256.
  • Zhou N, Nowicka-Sans B, McAuliffe B, et al. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. J Antimicrob Chemother. 2014;69:573-581.
  • Andreatta K, Acosta R, DaAntoni ML, et al. Prevalence and Risk Factors of Preexisting NNRTI Resistance Among Suppressed PLWH in B/F/TAF Switch Studies. Program and abstracts of the 23rd International AIDS Conference. July 6-10, 2020. Virtual. Abstract PEB0254.
  • Asante-Appiah E, Lai J, Li Q, et al. Doravirine Resistance Profile in Clinical Isolates and Impact of Baseline NNRTI Resistance-Associated Mutations Observed in Treatment-Naïve Participants from Phase 2 and 3 Clinical Trials. Program and abstracts of the 23rd International AIDS Conference. July 6-10, 2020. Virtual. Abstract PDB0406.
  • Baxter JD, Dunn D, Marvig RL, et al. Pretreatment HIV Drug Resistance in the START Study using Next Generation Sequencing. Program and abstracts of the 2018 Conference on Retroviruses and Opportunistic Infections. March 4-7, 2018. Boston, MA. Abstract 527.
  • Blanco JL, Oldenbuettel C, Thomas R, et al. Pathways of resistance in subjects failing dolutegravir monotherapy. 2017 Conference on Retroviruses and Opportunistic Infections. February 13-16, 2017. Seattle, WA. Abstract 42.
  • Chaix ML, Grude M, Delagreverie H, et al. High Prevalence of NNRTI and INI-resistant polymorphic virus in primary HIV infection. Program and abstracts of the 2018 Conference on Retroviruses and Opportunistic Infections. March 4-7, 2018. Boston, MA. Abstract 529.
  • De Meyer S, Dierynck I, Lathouwers E, et al. Identification of mutations predictive of a diminished response to darunavir/ ritonavir: Analysis of data from treatment-experienced patients in POWER 1, 2, 3, and DUET-1 and DUET-2. Programs and abstracts of the 6th European HIV Drug Resistance Workshop; March 26-28, 2008; Budapest, Hungary. Abstract 54.
  • De Miguel, Rial D, Dominguez-Dominguez L, et al. Long-term DTG+3TC switch efficacy in patients with archived 3TC resistance. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. Boston, Massachusetts (Virtual). Abstract 146.
  • Deschanvres C, Raffi F, Reynes J, et al. Virologic failure and resistance in dolutegravir-based maintenance dual regimens. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. Boston, Massachusetts (Virtual). Abstract 490.
  • Emu B, Lalezari J, Kumar P, et al. Ibalizumab: 96-week data and efficacy in patients resistant to common antiretrovirals. Program and abstracts of the 2019 Conference on Retroviruses and Opportunistic Infections. March 4-7, 2019. Seattle, WA. Abstract 485.
  • Henegar C, Underwood M, Ragone L, et al. Trends and characteristics of HIV-1 drug resistance in the United States (2012-2018). Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. Boston, MA (Virtual). Abstract 521.
  • Misra K, Jamie Huang J, Daskalakis DC, Udeagu CC. Impact of PrEP on drug resistance and acute HIV infection, New York City, 2015-2017. Program and abstracts of the 2019 Conference on Retroviruses and Opportunistic Infections. March 4-7, 2019. Seattle. Abstract 107.
  • Wang R, Wright J, Khaled, et al. Assessing the virologic impact of archived resistance in an HIV-1 Switch Study TANGO Through Week 48. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. Boston, Massachusetts (Virtual). Abstract 59.
  • Weinheimer S, Marsolais C, Cohen Z, et al. Ibalizumab susceptibility in patient HIV isolates resistant to Antiretrovirals. Program and abstracts of the 2018 Conference on Retroviruses and Opportunistic Infections. March 4-7, 2018. Boston, MA. Abstract 561.
  • Yang D, Lai J, Cal S, et al. HIV resistance-associated mutations observed in cell-associated DNA sequencing assay. Program and abstracts of the 2019 Conference on Retroviruses and Opportunistic Infections. May 4-7, 2019. Seattle, WA. Abstract 543.

Thank you for visiting the AAHIVM Provider Education Center! 

In order to continue, we will need you to create a profile. This will help us keep track of your education activity and CME accreditations.

           NEW USERS CLICK HERE TO CREATE A PROFILE.           

ALREADY CREATED YOUR AAHIVM PROFILE? CLICK HERE TO SIGN IN.

Are you an AAHIVM member? If not, consider supporting the Academy and programs like these. Click here to become an Academy member.

 

Connect

Phone: 202-659-0699
Fax: 202-659-0976

Contact

AAHIVM National Office
1627 Eye St NW Suite 835
Washington, D.C. 20006

About

The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.